Clinical trials: Minimal Change Nephrotic Syndrome (MCNS)
Minimal Change Nephrotic Syndrome (MCNS)
RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome
Minimal change nephrotic syndrome (MCNS) is an acquired glomerular disease characterized by massive proteinuria occurring in the absence of glomerular inflammatory lesions or immunoglobulin deposits.
- Trial name
- RIFIREINS (NCT03970577)
- Testing
- Rituximab, Prednisone
- Where
- France
- Volunteers
- 148 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nephrosis, Lipoid
Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study
Study objective: To investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syndrome (MCNS).
- Trial name
- NCT01185197
- Testing
- Myfortic plus low-dose steroid, Prednisolone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
MCNS, Minimal Change Nephrotic Syndrome (MCNS)
A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome
To compare the therapeutic effect of tacrolimus in combination with low-dose corticosteroid with high-dose corticosteroid alone in patients with minimal-change nephrotic syndrome.
- Trial name
- T-OPTIMUM (NCT01763580)
- Testing
- Tacrolimus, Prednisolone
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Astellas Pharma Korea, Inc.